Femme et Homme | 18 ans et plus
- | Pays :
- France
- | Organes :
- Tumeurs stromales digestives (GIST)
- | Spécialités :
- Thérapies Ciblées
Extrait
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment.
Extrait Scientifique
en cours d'intégration;